Tissue Dynamics
Tel Aviv, Israel· Est.
AI‑powered organoid platform that delivers real‑time human physiology data to accelerate drug discovery and de‑risk development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered organoid platform that delivers real‑time human physiology data to accelerate drug discovery and de‑risk development.
OncologyImmunologyNeurologyCardiology
Technology Platform
AI‑driven MechaniX software reconstructs metabolic networks for target and toxicity prediction, while DynamiX sensors provide real‑time functional readouts from thousands of human organoids in parallel.
Opportunities
Expanding pharma collaborations and integrating multi‑omics data could unlock new revenue streams and broaden therapeutic applications.
Risk Factors
Reliance on partner pipelines and validation of predictive accuracy across diverse disease models pose execution and adoption risks.
Competitive Landscape
Competes with organ‑on‑a‑chip and organoid platforms (e.g., Emulate, InSphero) but differentiates through AI‑driven network modeling and high‑throughput parallel organoid screening.